• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Finance

Finance

Kanvas Biosciences Secures $48M Series A to advance lead immuno-oncology drug

May 8, 2026 Microbiome Times

Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC. Additional participating investors include Gates Foundation, ATHOS […]

Finance

EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS

April 30, 2026 Microbiome Times

EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome […]

Finance

mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome Therapeutics

April 28, 2026 Microbiome Times

mbiomics GmbH, a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases, today announced the successful third closing of its Series A round at €12 million, bringing the total round size to […]

Finance

Women’s Health Innovation Is Not Failing – The System Around It Is

March 31, 2026 Maria Katsarou and Chrysi Sergaki

Women’s health is not constrained by a lack of scientific progress, but by systems that fail to recognise, prioritise, and translate it. Until those systems evolve, even the most promising innovations will struggle to reach […]

Finance

Opella announces strategic partnership with Verb Biotics for development of next-generation probiotic strain

March 13, 2026 Microbiome Times

Opella announces a strategic and exclusive partnership with Verb Biotics for the development of a next-generation probiotic strain and its commercialization. This collaboration merges Opella’s ability to take ideas from concept to execution at global […]

Finance

Ascribe Bio Closes $12 Million Series A Financing to Advance Next-Generation Natural Crop Protection

November 3, 2025 Microbiome Times

Ascribe Bio, an innovator in natural crop protection, announced the closing of an oversubscribed $12 million Series A financing round, co-led by Corteva, through its Corteva Catalyst platform, and Acre Venture Partners. The financing also included participation […]

Finance

Seres Therapeutics Receives Award of up to $3.6M from Carb-X to Develop Liquid Formulation of Ser-155

October 31, 2025 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, announced that CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, will provide up to $3.6 million in additional non-dilutive funding to […]

Finance

EXPERT’Biome, CDMO By Lallemand, Acquires Bacthera Equipment

September 9, 2025 Microbiome Times

Following the closure of Bacthera’s CDMO activities, Lallemand has acquired a broad range of state-of-the-art equipment to produce drug substances and drug products in anaerobic conditions, reinforcing its GMP Pharma production capabilities for next-generation strains. […]

Finance

SNIPR BIOME Raises EUR 35 Million Series B Financing

August 7, 2025 Microbiome Times

COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) — SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from […]

Finance

BioGaia launches subsidiary company dedicated to advancing microbiome research and innovation

July 21, 2025 Microbiome Times

As interest in biotics1 and their wide range of health applications continues to grow, BioGaia is proud to announce the launch of a subsidiary company, BioGaia New Sciences AB, dedicated to exploring opportunities in microbiome […]

Finance

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg®

July 2, 2025 Nick Gallo

MaaT Pharma announces the signature of a license and commercial agreement with Clinigen, a global specialty pharmaceutical services group and a leading European player in hospital distribution and market access, to streamline the pathway for […]

Posts navigation

1 2 … 32 »

Sign Up to Free Newsletter

QIAGEN WEBINAR SERIES – REGISTER HERE

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
    May 1, 2026
  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
sign up

Sign up to the Microbiome Times newsletter